Clinical Trials Logo
  1. Home
  2. Oral Lichen Planus
  3. NCT05139667
  4. Details
NCT05139667 Clinical Trial

Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus

Oral Lichen Planus Clinical Trial

Official title:
Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus ( A Randomized Controlled Clinical Trial With Immunohistochemical Analysis)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05139667
Other study ID # FDASU-RECD123
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 20, 2019
Est. completion date October 20, 2021

Study information
Verified date November 2021
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

tacrolimus has been widely used as an immunosuppressant. the objective of this study was to evaluate the clinical efficacy of tacrolimus 0.1 % in muco adhesive patch compared to tacrolimus or corticosteroids in paste forms for symptomatic oral lichen planus, and to investigate the effect of topical tacrolimus or corticosteroids on the expression of caspase-3 in oral lichen planus as an early marker of apoptosis using immunohistochemically analysis

Description:

thirty patients with erosive or atrophic OLP were randomly assigned into three equal groups to receive topical steroid ( triamcinolone acetonide 0.1%), four times per day ( Group 1), tacrolimus paste 0.1% four times per day ( Group 2) , and tacrolimus patch 2 times per day ( Group 3). all groups are given treatment for 8 weeks and 4 weeks follow up period without treatment. Photographs of the most severe lesion were taken ( marker lesion ) in each patient and analyzed for total ulcerative area (TUA), total atrophic area (TAA). patients were also assessed using clinical scores (CS) and visual analogue scale (VAS). pre treatment and post treatment specimens were immunohistochemically stained to detect expression of caspase-3.

Recruitment information / eligibility
Status Completed
Enrollment 30
Est. completion date October 20, 2021
Est. primary completion date October 20, 2021
Accepts healthy volunteers No
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria: - clinically and histologically proven painful bullous/erosive or atrophic forms of OLP Exclusion Criteria: - lichenoid lesions smoking systemic conditions pregnancy or breast feeding known hypersnstivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Corticosteroid Topical
topical tacrolimus and corticosteroids

Locations
Country Name City State
Egypt Noha Dawoud Cairo

Sponsors (1)
Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary clinical score "0" represnted no lesion/normal mucosa, "1" mild white stria / no erythematous area change from baseline at 12 weeks
Secondary caspase-3 caspase-3 cells count in immunostained section change from base line at 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05997173 - The Regulatory Role of Immune Response in Oral Lichen Planus
Completed NCT02443311 - Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus Phase 4
Completed NCT00484250 - Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other Phase 2
Completed NCT03682562 - Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
Not yet recruiting NCT06428630 - Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus Early Phase 1
Completed NCT04193748 - Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial) Phase 4
Completed NCT04153266 - Oral Epithelial Dysplasia Informational Needs Questionnaire
Recruiting NCT06135805 - Impact of Fluocinonide 0,05% in Oral Lichen Planus N/A
Completed NCT04289233 - Molecular & Cellular Characterisation of Oral Lichen Planus
Completed NCT04293718 - Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
Completed NCT00525421 - A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus Phase 2
Not yet recruiting NCT04091698 - Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial Phase 1
Completed NCT03386643 - Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus Phase 2
Withdrawn NCT03836885 - Apremilast - Oral Lichen Planus Trial Phase 2
Completed NCT05730855 - Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
Completed NCT03257228 - The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2) N/A
Recruiting NCT03026478 - Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus Phase 2
Completed NCT02834520 - Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus N/A
Completed NCT02858297 - Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus Phase 4
Completed NCT02106468 - The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus Phase 2